I think maybe the money's what's throwing you off here today.
Followers | 199 |
Posts | 17,218 |
Boards Moderated | 2 |
Alias Born | 02/17/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gm ocuhub
OCGN
Shankar got shares? HOLDING. Bears will be bears.
OCGN
Shankar got shares? HOLDING. Bears will be bears.
OCGN
OCGN Earnings call Aug 8, 830am et
https://ir.ocugen.com/news-releases/news-release-details/ocugen-host-conference-call-thursday-august-8-830-am-et-discuss
Gm ocuhub
OCGN
Holding
OCGN
Gm ocuhub. HOLDING.
OCGN
Holding
OCGN
Gm ocuhub.
Added this week and holding.
OCGN
That language doesn’t fly on ihub. Keep it clean and don’t risk getting booted.
Holding
OCGN buying and holding
Gm ocuhub. Company has cash. I like it.
Good evening, ocuhub
OCGN
OCGN nasdaq compliance next week
OCGN nasdaq compliance next week.
Gm ocuhub. HOLDING
OCGN
1.06 going
OCGN
Good afternoon, ocuhub
OCGN
Gm harry.
OCGN
Good afternoon, Ocuhub.
OCGN
.53 seller out
Gm ocuhub
Gm ocuhub
OCGN
OCGN .60 break
.60 pm
OCGN
Gm ocuhub
“Project NextGen will also support 10 to 15 phase 1 trials and 6 to 8 phase 2 trials at the NIAID, Beigel said. Companies will provide their vaccine candidates, while the NIAID will cover the costs of the trials.”
“Ocugen is the other company that has publicized its vaccine’s selection for NIAID trials. Its mucosal vaccine uses a chimp adenovirus to deliver the SARS-CoV-2 spike protein. Although the vaccine hasn’t yet been tested in humans in the US, it has completed phase 1, 2, and 3 trials in India, where, in the form of nose drops, it was authorized more than a year ago as a primary vaccine as well as a mix-and-match booster.”
https://jamanetwork.com/journals/jama/fullarticle/2812830
OCGN